
Skinvisible ( ($SKVI) ) has released a notification of late filing. Skinvisible, Inc. has filed a Form 12b-25, notifying the delay of its Form 10-K (Yearly Report) for the financial
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SKVI | Skinvisible | 0.18 | -0.17 | -48.57% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.18 | -48.57% |

Skinvisible ( ($SKVI) ) has released a notification of late filing. Skinvisible, Inc. has filed a Form 12b-25, notifying the delay of its Form 10-K (Yearly Report) for the financial

Skinvisible ( ($SKVI) ) has issued an update. Skinvisible announced significant achievements in 2024 and 2025 through its licensee, Quoin Pharmaceuticals, which has made progress in treating Netherton Syndrome using

Skinvisible announced the publication of an article highlighting the Company’s innovative development of transdermal delivery of glucose-controlling agents using its proprietary delivery system Invisicare. The article, titled “Advancements in Transdermal

Skinvisible ( ($SKVI) ) has provided an announcement. Skinvisible Pharmaceuticals has announced the development of a cutting-edge transdermal obesity treatment utilizing its proprietary Invisicare technology, which delivers medication through the

Skinvisible Pharmaceutical announced data demonstrating its transdermal delivery of obesity drugs including a GLP-1 agonist and CB-1 receptor antagonist delivered by its proprietary Invisicare technology; a polymer delivery vehicle that

Skinvisible Pharmaceuticals announced the filing of a second patent application for its Invisicare technology and its transdermal delivery of obesity and glucose-controlling agents. This new application significantly broadens the scope

Skinvisible (SKVI) has provided an update. On May 29, 2024, a press release announced the filing of a Provisional Patent Application for a novel transdermal delivery composition designed to administer

Skinvisible (SKVI) shared an update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals (QNRX). The trials focus on the innovative formulation “QRX003,” powered by Skinvisible’s Invisicare proprietary
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.